Targeted Contrast Agents for MRI Relaxivity and Safety
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current MRI contrast agents are non-specific, leading to inefficient targeting of specific cells and tissues, resulting in low relaxivity and short circulation time, which limits their effectiveness in diagnostic imaging, especially in detecting early tumor lesions and metastases.
Innovation Solution
Development of targeted contrast agents comprising a peptide or protein moiety linked to a contrast protein with metal ion binding sites, allowing specific accumulation and retention in target cells, reducing exposure to normal cells and enhancing image contrast.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If non-specific small molecule contrast agents are used, then the contrast agents can be administered easily, but they have short circulation time and low relaxivity
Solution Approach 1:
The patent creates composite contrast agents by covalently linking small molecule contrast agents (such as Gd-DTPA) to macromolecules (such as dendrimers, copolymers, or proteins). This composite structure combines the advantages of both components: the small molecule provides high relaxivity and the macromolecule provides extended circulation time through reduced renal clearance. The contrast agent thus achieves both ease of administration and prolonged circulation.
2Reliability
If non-specific contrast agents are used, then they can improve intrinsic contrast, but they expose normal cells to heavy metals unnecessarily
Solution Approach 1:
The patent introduces targeting moieties (such as antibodies, peptides, or ligands) that specifically recognize and bind to receptors or markers on target cells (such as tumor cells). This creates local concentration of the contrast agent at the disease site while minimizing distribution to normal tissues. The targeting component ensures that the heavy metal contrast agent is delivered preferentially to pathological tissues, reducing harmful exposure to normal cells while maintaining contrast improvement.
3Manufacturing precision
If contrast agents are administered at high doses to achieve sufficient contrast, then image quality improves, but the exposure to heavy metals increases
Solution Approach 1:
The composite structure of macromolecule-linked contrast agents provides prolonged circulation time, allowing the use of lower doses while achieving sufficient contrast enhancement. The extended circulation enables longer imaging windows and better tissue accumulation, reducing the need for high doses.
Solution Approach 2:
Targeted delivery concentrates the contrast agent at the disease site, increasing the local concentration where it is needed most. This allows for lower overall administered doses while achieving the same or better image quality at the target, thereby reducing systemic heavy metal exposure.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The targeted contrast agents provide improved diagnostic imaging by increasing relaxivity, reducing normal cell exposure to heavy metals, and enabling more efficient delivery to specific tissues, thereby enhancing image quality and safety.
Implementation Method 1
a contrast protein that is preferably a contrast agent and can be an organic polymer such as a protein having at least one metal ion binding site capable of chelating paramagnetic and heavy metal ions
Data Source
AI summary
A contrast agent having a contrast protein have contrast properties and at least one targeting moiety, wherein the at least one targeting moiety is operatively linked to or incorporated within the contrast protein. Methods for targeting contrast agents and for preparing such agents are included.